Maze in the news
User research platform
Tamtam found 19 recent articles about Maze.
- Insider Sale: President of $MAZE Sells 16,142 Shares
Harold Bernstein, President of $MAZE, sold all his shares amid widespread insider selling, mixed hedge fund activity, and positive analyst ratings.
- CEO Coloma trusts trim 1,938 Maze Therapeutics (MAZE) shares under 10b5-1 plan
CEO Jason V. Coloma sold 1,938 shares of Maze Therapeutics common stock at $26.00 per share through family trusts.
- Maze Therapeutics Announces Sizable $150M Growth Offering
Maze Therapeutics raised $150 million to advance two key drug programs, MZE829 and MZE782, into later development stages and fund operations into 2029.
- Liquidity Mapping Around (MAZE) Price Events
MAZE Corporation faces weak near and mid-term sentiment, no clear price positioning, and elevated downside risk, while AI models offer tailored trading strategies for different risk profiles.
- Près de Nantes : Fanny fabrique des bières fruitées, "j'aime la partie chimiste"
Fanny, a brewer near Nantes, specializes in creating pure-tasting, fruit-infused beers with original recipes, focusing on gradual, quality-driven growth.
- Maze Therapeutics progresse grâce aux résultats positifs de l'essai d'un médicament contre les maladies rénale
Maze Therapeutics reports positive mid-stage trial results for its kidney disease drug MZE829, showing significant protein reduction in urine.
- BTIG réitère sa recommandation sur l’action Maze Therapeutics suite aux résultats d’essai
BTIG and other analysts maintain strong buy ratings on Maze Therapeutics following positive trial results for its kidney disease treatment, MZE829.
- Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop (NASDAQ:MAZE)
Maze Therapeutics advances its MZE829 drug with strong phase 2 results despite a 37% stock price drop.
- Mizuho réitère sa note sur l’action Maze Therapeutics après les données de phase 2
Maze Therapeutics' MZE829 showed strong Phase 2 results with significant efficacy in AMKD and FSGS patients, prompting a Mizuho Outperform rating and $97 price target despite recent quarterly losses.
- Maze annonce des résultats positifs de phase 2 pour un médicament contre les maladies rénales
Maze Therapeutics announced promising phase 2 trial results showing that their oral APOL1 inhibitor MZE829 reduces kidney disease markers in APOL1-mediated kidney disease patients with good tolerability.
- La valeur boursière de Maze Therapeutics chute malgré de solides données sur le médicament rénal de phase 2 MZE829
Maze Therapeutics' stock fell despite positive Phase 2 results showing MZE829 effectively reduces proteinuria in APOL1-mediated kidney disease and FSGS patients, with plans to advance the drug.
- Wedbush Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $58
Wedbush maintains a buy rating and $58 target price on Maze Therapeutics, with the analyst showing moderate success and returns historically.
- Harold Bernstein Sells 15,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock
Maze Therapeutics' CMO sold substantial company shares recently amid generally positive analyst ratings and notable institutional buying in a clinical-stage biotech focused on genetics-based therapeutics.
- Maze Therapeutics (NASDAQ:MAZE) CMO Sells 30,000 Shares
Maze Therapeutics' CMO sold significant shares amid strong stock performance and positive analyst ratings for its genetics-driven drug discovery pipeline.
- Maze Therapeutics Executive Sells All Common Stock Holdings
Maze Therapeutics' President and CMO sold all his 30,000 shares for about $1.51 million on March 10, 2026.
- Maze Therapeutics stock hits all-time high at 49.28 USD
Maze Therapeutics stock hit a record high amid strong investor confidence driven by promising clinical data and positive analyst outlooks.
- Maze Therapeutics (NASDAQ:MAZE) Shares Up 8.5% - Here's Why
Maze Therapeutics' stock surged 8.5% amid positive analyst ratings and institutional buying, despite insider selling, as it advances its genetics-based drug discovery pipeline.
- Discipline and Rules-Based Execution in MAZE Response
MAZE stock faces weak near-term sentiment with resistance testing and AI-driven trading strategies highlighting a high risk-reward short opportunity amid volatile conditions.
- Maze Therapeutics, Inc. (NASDAQ:MAZE) Sees Significant Growth in Short Interest
Maze Therapeutics saw a notable rise in short interest and insider selling amid mixed analyst ratings and increased institutional investment.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Maze?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies